CD274 and non-small cell lung carcinoma: This study aims to evaluate real-world outcomes of pembrolizumab monotherapy in patients with advanced and metastatic NSCLC and high PD-L1 expression, with a particular focus on overall survival and treatment response compared to results from the KEYNOTE-024 trial.